Bayer AG and plaintiffs lawyers have reached a $1.6 billion proposed agreement to resolve U.S. injury claims involving its female sterilization device Essure. The settlement includes in all jurisdictions with high volumes of Essure litigation, such as the coordinated cases in California and lawsuits in the U.S. District Court for the Eastern District of Pennsylvania, Bayer reports, resolving about 90% of the nearly 39,000 total claims that the implant caused side effects such as hair and tooth loss, chronic bleeding, miscarriages and death of both Essure recipients and their infants.
“With the settlements, Bayer resolves virtually all of the U.S. Essure litigation so that the company can focus on its commitment to women’s health, where it has long been a leader, without the distractions and uncertainties associated with this litigation,”Bayer said in a statement. The company stated in a news release that there is no admission of wrongdoing or liability by Bayer in the settlement agreements.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]